Page 40 - Platform Technology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

/PRNewswire/ -- Soreness is a normal part of strenuous physical activity. It can develop during a workout, a pickup soccer game, a formally organized sport, or...

Total potential deal value up to $2 billion plus tiered royalties on commercial salesSynaffix to provide Amgen access to its proprietary antibody-drug conjugate (ADC) technologiesAMSTERDAM,

Automate with cloud ERP? Maybe. Personalize? Rarely seen. But all that and more is happening at Combilift. During a revealing session with the Combilift...

Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies Synaffix to receive up to $150m in upfront and milestone payments plus royalties SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Hummingbird Bioscience (Hummingbird Bio), a data-driven precision biotherapeutics company using its Rational Antibody Discovery (RAD) platform to discover an...

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies Synaffix to receive up to $150m in upfront and milestone payments plus royalties   Amsterdam...